Onco-Summaries: Daily Oncology Updates at a Glance

04/02/2026

---

• Oncolytics Biotech's pelareorep-based regimen received the FDA fast track designation for MSS CRC

---

Oncolytics Biotech's pelareorep-based regimen received the FDA fast track designation for MSS CRC (Ref)

The US FDA granted the fast track designation to Oncolytics Biotech's pelareorep (oncolytic virus) in combination with bevacizumab (Avastin®) and FOLFIRI for the treatment of patients with KRAS-mutant, MSS metastatic colorectal cancer in the second-line setting.

• The designation is supported by clinical data demonstrating a 33% ORR for pelareorep-based therapy compared to approximately 10% ORR with SOC in this patient population

  
  

• Oncolytics expects to initiate a controlled clinical study in second-line KRAS-mutant MSS mCRC comparing standard-of-care therapy alone versus standard-of-care plus pelareorep